Condition (MeSH)
Lymphoma, Primary Effusion
ClinicalTrials.gov lists 19 trials for Lymphoma, Primary Effusion or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 9.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Lymphoma, Primary Effusion itself; the rest are tagged with a narrower condition beneath it.
When did Lymphoma, Primary Effusion trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2021 | 4 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2014 | 1 |
| 2010 | 2 |
| 2005 | 2 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lymphoma, Primary Effusion trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 4 |
| Phase 2 | 5 |
| Not applicable | 2 |
| Observational | 4 |
How many Lymphoma, Primary Effusion trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Completed | 7 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lymphoma, Primary Effusion trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 9 |
| AIDS Malignancy Consortium | 1 |
| Catherine Bollard | 1 |
| Estrella Immunopharma, Inc. | 1 |
| Schrödinger, Inc. | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Lymphoma, Primary Effusion? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 5 |
| RITUXIMAB | 4 |
| Prednisone | 4 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Doxorubicine | 4 |
| Etoposid | 4 |
| Vincristina | 4 |
| HST-NEETs | 1 |
| Pegylated Liposomal Doxorubicin (Doxil) and Rituximab | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lymphoma, Primary Effusion trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Relapse | 25 | 1 |
| Neutrophil Count Decreased | 21 | 1 |
| Febrile Neutropenia | 19 | 1 |
| Disease progression | 17 | 2 |
| Platelet Count Decreased | 14 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Lymphoma, Primary Effusion? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression. | Oncotarget | 2015 | Yes |
| Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors. | Oncogene | 2014 | Yes |
| Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. | Molecular cancer therapeutics | 2014 | Yes |
| Inflammasome activation in patients with Kaposi sarcoma herpesvirus-associated diseases. | Blood | 2024 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Primary effusion lymphoma | Cases families | Worldwide | Not stated | Exact | |
| Primary effusion lymphoma | Cases families | Worldwide | Not stated | Unspecified | |
| Primary effusion lymphoma | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Primary effusion lymphoma | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Primary effusion lymphoma | Cases families | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Primary effusion lymphoma | 48686 | Exact | Orphadata Science knowledge files, Product 1 |
| Primary effusion lymphoma | 48686 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.